Broad Institute of MIT and Harvard University, Cambridge, MA, USA; Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, MA, USA; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
Department of Biochemistry & Cell Biology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA; National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
Cell Rep. 2024 Jan 23;43(1):113596. doi: 10.1016/j.celrep.2023.113596. Epub 2023 Dec 20.
Targeted synthetic vaccines have the potential to transform our response to viral outbreaks, yet the design of these vaccines requires a comprehensive knowledge of viral immunogens. Here, we report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) peptides that are naturally processed and loaded onto human leukocyte antigen-II (HLA-II) complexes in infected cells. We identify over 500 unique viral peptides from canonical proteins as well as from overlapping internal open reading frames. Most HLA-II peptides colocalize with known CD4 T cell epitopes in coronavirus disease 2019 patients, including 2 reported immunodominant regions in the SARS-CoV-2 membrane protein. Overall, our analyses show that HLA-I and HLA-II pathways target distinct viral proteins, with the structural proteins accounting for most of the HLA-II peptidome and nonstructural and noncanonical proteins accounting for the majority of the HLA-I peptidome. These findings highlight the need for a vaccine design that incorporates multiple viral elements harboring CD4 and CD8 T cell epitopes to maximize vaccine effectiveness.
靶向合成疫苗有可能改变我们对病毒爆发的应对方式,但这些疫苗的设计需要全面了解病毒免疫原。在这里,我们报告了严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)在感染细胞中自然加工并加载到人类白细胞抗原-II(HLA-II)复合物上的肽段。我们从规范蛋白以及重叠的内部开放阅读框中鉴定出超过 500 个独特的病毒肽段。大多数 HLA-II 肽段与 2019 年冠状病毒病患者中的已知 CD4 T 细胞表位共定位,包括 SARS-CoV-2 膜蛋白中的 2 个报道的免疫优势区域。总体而言,我们的分析表明 HLA-I 和 HLA-II 途径靶向不同的病毒蛋白,结构蛋白占 HLA-II 肽组的大部分,非结构和非规范蛋白占 HLA-I 肽组的大部分。这些发现强调了需要设计一种包含多个携带 CD4 和 CD8 T 细胞表位的病毒元件的疫苗,以最大限度地提高疫苗的有效性。